Oxurion cancels its project in France to focus on an international target

The Belgian biopharmaceutical company, Oxurion NV, has decided to halt its planned acquisition of a majority stake in a French Contract Research Organization (CRO). This decision follows a thorough evaluation that did not confirm the conditions necessary for a successful acquisition. The company is now redirecting its resources toward a potential acquisition of an international CRO operating in Europe, North Africa, and the Middle East.

Oxurion is focusing on creating a cutting-edge, integrated clinical development platform that combines multi-country expertise with clinical data science. This strategy aims to strengthen its position in the international clinical services market.